765 reports of this reaction
4.1% of all THIOTEPA reports
#3 most reported adverse reaction
MUCOSAL INFLAMMATION is the #3 most commonly reported adverse reaction for THIOTEPA, manufactured by Amneal Pharmaceuticals LLC. There are 765 FDA adverse event reports linking THIOTEPA to MUCOSAL INFLAMMATION. This represents approximately 4.1% of all 18,516 adverse event reports for this drug.
Patients taking THIOTEPA who experience mucosal inflammation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUCOSAL INFLAMMATION is moderately reported among THIOTEPA users, representing a notable but not dominant share of adverse events.
In addition to mucosal inflammation, the following adverse reactions have been reported for THIOTEPA:
The following drugs have also been linked to mucosal inflammation in FDA adverse event reports:
MUCOSAL INFLAMMATION has been reported as an adverse event in 765 FDA reports for THIOTEPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUCOSAL INFLAMMATION accounts for approximately 4.1% of all adverse event reports for THIOTEPA, making it one of the most commonly reported side effect.
If you experience mucosal inflammation while taking THIOTEPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.